1393843-02-1

Basic information

• Product Name: 2-(2-chloro-6-fluorophenyl)-7-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,4-dimethyl-1,4-dihydro-chromeno[3,4-d]imidazole
• Synonyms: 2-(2-chloro-6-fluorophenyl)-7-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,4-dimethyl-1,4-dihydro-chromeno[3,4-d]imidazole
• CAS NO: 1393843-02-1
• Molecular Weight: 436.873
• Mol File: 1393843-02-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(2-chloro-6-fluorophenyl)-7-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,4-dimethyl-1,4-dihydro-chromeno[3,4-d]imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-chloro-6-fluorophenyl)-7-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,4-dimethyl-1,4-dihydro-chromeno[3,4-d]imidazole(1393843-02-1)
• EPA Substance Registry System: 2-(2-chloro-6-fluorophenyl)-7-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,4-dimethyl-1,4-dihydro-chromeno[3,4-d]imidazole(1393843-02-1)

Safety Data

• Hazardous Substances Data: 1393843-02-1(Hazardous Substances Data)

Upstream product

• 934388-20-2 ethyl 4-acetyl-3-hydroxybenzoate 
• 51285-13-3 N’-hydroxycyclopropanecarboximidamide 
• 1393843-91-8 2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-1,4-dihydrochromeno[3,4-d]imidazole-7-carboxylic acid 
• 1393843-92-9 ethyl 2,2-dimethyl-3,4-dioxochromane-7-carboxylate 
• 191611-56-0 ethyl 2,2-dimethyl-4-oxochromane-7-carboxylate 
• 1393843-93-0 ethyl 2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-1,4-dihydrochromeno[3,4-d]imidazole-7-carboxylate 
• 51285-13-3 cyclopropanecarboxamide oxime 

Relevant articles and documents

Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model

A series of substituted tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives have been synthesized and their mPGES-1 biological activity has been disclosed in detail. Structure-activity relationship (SAR) optimization provided inhibitors with excellent mPGES-1 potency and low to moderate PGE2 release A549 cell potency. Among the mPGES-1 inhibitors studied, 7, 9 and 11l provided excellent selectivity over COX-2 (>200-fold) and >70-fold selectivity for COX-1 except 11l, which exhibited dual mPGES-1/COX-1 activity. Furthermore, the above tested mPGES-1 inhibitors demonstrated good metabolic stability in liver microsomes, high plasma protein binding (PPB) and no significant inhibition observed in clinically relevant CYP isoforms. Besides, selected mPGES-1 tool compounds 9 and 11l provided good in vivo pharmacokinetic profile and oral bioavailability (%F?=?33 and 85). Additionally, the representative mPGES-1 tool compounds 9 and 11l revealed moderate in vivo efficacy in the LPS-induced thermal hyperalgesia guinea pig pain model.